Yaron Carmi, PhD
Dr. Carmi worked as a postdoctoral fellow at Stanford University with Prof. Edgar G. Engleman, where he focused on understanding the key factors by which tumor-associated dendritic cells process molecules as foreign antigens.
He completed his PhD studies summa cum laude at the Immunology Department in Ben-Gurion University, under the supervision of Prof. Ron N. Apte and won a number of academic excellence awards. He studied Biotechnology in Tel-Hai Collage, where he worked under the supervision of Prof. Gidi Gross, one of the researchers who developed the chimeric T cell receptor (CAR) therapy.
Peleg Rider, PhD
Dr. Peleg Rider received his Ph.D from the Department of Immunology in Ben-Gurion University, under the supervision of prof. Ron N. Apte. His research focused on the role of the inflammatory cytokines IL-1alpha and IL-1beta in the sterile inflammatory process. In his post-Doc research, Peleg developed an anti-inflammatory protein, which is activated by the inflammatory process, known as “chimeric-IL-1Ra”, under the supervision of prof. Lewis from BGU and prof. Dinarello from the university of Colorado.
Mrs Santana-Magal holds an engineering degree in biotechnology from the Tachnion and a M.Sc. in life science from Tel-Aviv University. Her PhD thesis focus on the route of antigen presentation by DC subsets during tumor progression and following immunotherapy.
Mrs Rasoloniriana holds an engineering degree in biotechnology from Ben-Gurion University of the Negev and a M.Sc. in life science from Ben-Gurion University. Her PhD thesis focus on isolating CD4 tumor-reactive T cells and on identify the checkpoints that regulate their activation during tumor progression and immunotherapy.
Mr. Gutwilling has discovered a unique subset of cancer cells, in both mice and humans, which can resistant to CD8+ T cell-mediated killing. These cells maintain high MHCI levels and do not lose their T cell-reactive antigen.
Mrs. Farahat works to generate immunotherapy that is based on monocytes bearing chimeric antigen receptors. She has discovered a unique signaling cascade in monocytes which can be harnessed to kill tumor cells.
Mr. Tal works to generate immunotherapy, based on a novel CD4+ T cell subset that was discovered in the lab.